Literature DB >> 11134650

Effect of YM-126414 on glucose uptake and redistribution of glucose transporter isotype 4 in muscle cells.

T Shimokawa1, M Kagami, M Kato, E Kurosaki, M Shibasaki, M Katoh.   

Abstract

We discovered a novel compound, YM-126414 [1,3, 3-trimethyl-2-(2-phenylaminovinyl)-3H-indolium perchlorate], which stimulates glucose uptake in skeletal muscle cells in vitro. This compound increased the rate of consumption of glucose by C2C12 mouse myoblast cells in a dose-dependent manner (EC(50)=10 nM). To investigate the mechanism of this stimulation, we determined the redistribution of insulin-regulatable glucose transporter isotype 4 (Glut4). When fully differentiated C2C12 cells stably expressing myc-tagged Glut4 protein were treated with YM-126414, redistribution was dramatically increased in a dose-dependent manner (EC(50)=21 nM). These results indicate that YM-126414 is a novel glucose uptake stimulator for muscle cells by causing up-regulation of Glut4 redistribution in differentiated muscle cells. Our findings for the in vitro effects of YM-126414 suggest a direction for the development of new drugs for the treatment of type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11134650     DOI: 10.1016/s0014-2999(00)00880-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

Review 1.  Skeletal muscle tissue engineering: methods to form skeletal myotubes and their applications.

Authors:  Serge Ostrovidov; Vahid Hosseini; Samad Ahadian; Toshinori Fujie; Selvakumar Prakash Parthiban; Murugan Ramalingam; Hojae Bae; Hirokazu Kaji; Ali Khademhosseini
Journal:  Tissue Eng Part B Rev       Date:  2014-02-24       Impact factor: 6.389

2.  Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2.

Authors:  A Suwa; T Yamamoto; A Sawada; K Minoura; N Hosogai; A Tahara; T Kurama; T Shimokawa; I Aramori
Journal:  Br J Pharmacol       Date:  2009-08-19       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.